Patents by Inventor Pinchas TSUKERMAN

Pinchas TSUKERMAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTIBODIES AGAINST NECTIN-2 AND DRUG CONJUGATES THEREOF
    Publication number: 20240424128
    Abstract: The present invention provides humanized monoclonal antibodies that recognize human Nectin-2 with high affinity and specificity and inhibit its binding to CD112R. These antibodies carry cytotoxic payload and do not interact with Fc gamma receptors. The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy.
    Type: Application
    Filed: August 28, 2024
    Publication date: December 26, 2024
    Inventors: Pinchas Tsukerman, Anas Atieh, Akram Obiedat, Guy Cinamon
  • HUMANIZED ANTIBODIES AGAINST NECTIN-2 AND DRUG CONJUGATES THEREOF
    Publication number: 20240409632
    Abstract: The present invention provides humanized monoclonal antibodies that recognize human Nectin-2 with high affinity and specificity and inhibit its binding to CD112R. These antibodies carry cytotoxic payload and do not interact with Fc gamma receptors. The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy.
    Type: Application
    Filed: August 28, 2024
    Publication date: December 12, 2024
    Inventors: Pinchas Tsukerman, Anas Atieh, Akram Obiedat, Guy Cinamon
  • ANTIBODIES SPECIFIC TO HUMAN NECTIN4
    Publication number: 20240376202
    Abstract: The present invention provides monoclonal antibodies that recognize human Nectin4 with high affinity and specificity and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy and in diagnosis.
    Type: Application
    Filed: July 23, 2024
    Publication date: November 14, 2024
    Inventors: Ofer MANDELBOIM, Adi RECHES, Stipan JONJIC, Pinchas TSUKERMAN
  • Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT)
    Patent number: 12121579
    Abstract: Natural killer (NK) cell killing of various tumors is inhibited in the presence of ligands of TIGIT, an inhibitory receptor present on all human NK cells and on various T cells. Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions comprising them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: October 22, 2024
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
    Inventors: Ofer Mandelboim, Noa S. Kaynan, Pinchas Tsukerman, Stipan Jonjic
  • Antibodies specific to human NECTIN4
    Patent number: 12077583
    Abstract: The present invention provides monoclonal antibodies that recognize human Nectin4 with high affinity and specificity and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy and in diagnosis.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: September 3, 2024
    Assignees: NECTIN THERAPEUTICS LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW
    Inventors: Ofer Mandelboim, Adi Reches, Stipan Jonjic, Pinchas Tsukerman
  • ANTIBODIES AGAINST CD112R AND USES THEREOF
    Publication number: 20240270840
    Abstract: The present invention provides monoclonal antibodies that recognize human CD 112R with high affinity and specificity and inhibit its binding to Nectin-2. The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy and in diagnosis.
    Type: Application
    Filed: February 9, 2022
    Publication date: August 15, 2024
    Applicants: NECTIN THERAPEUTICS LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Pinchas TSUKERMAN, Anas ATIEH, Akram OBIEDAT, Guy CINAMON, Stipan JONJIC, Tihana LENAC ROVIŠ, Paola KUCAN BRLIC, Ofer MANDELBOIM
  • ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR)
    Publication number: 20240018257
    Abstract: The present invention provides monoclonal antibodies that recognize poliovirus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.
    Type: Application
    Filed: August 15, 2023
    Publication date: January 18, 2024
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
    Inventors: Ofer MANDELBOIM, Noa S. KAYNAN, Pinchas TSUKERMAN, Stipan JONJIC
  • ANTIBODIES AGAINST THE POLIOVIRUS RECEPTOR (PVR) AND USES THEREOF
    Publication number: 20220372161
    Abstract: The present invention provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies are useful in the treatment of tumors or cancers.
    Type: Application
    Filed: October 7, 2020
    Publication date: November 24, 2022
    Applicant: NECTIN THERAPEUTICS LTD.
    Inventors: Philipp ALBERTS, Arif JETHA, Johan FRANSSON, Yazen JMEIAN, Joanne HULME, Pinchas TSUKERMAN
  • ANTIBODIES SPECIFIC TO HUMAN NECTIN-2
    Publication number: 20220112283
    Abstract: The present disclosure provides monoclonal antibodies that recognize human Nectin-2 (Nectin-2, Poliovirus Receptor-Related Protein-2, Poliovirus Receptor-Like 2, CDI12, or PRR-2, is a single pass transmembrane glycoprotein with two Ig-like C2-type domains and an Ig-like V-type domain) with high affinity and specificity and inhibit its binding to TIGIT and/or CD112R. The antibodies recognize the Nectin-2 protein (CD112), prevent its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD112R (PVRIG) and inhibit suppressive activity on lymphocytes such as natural killer (NK) cells and T-cells. The disclosure further provides pharmaceutical and methods for use in cancer immunotherapy and in diagnosis. The disclosure finally further provides chimeric antigen receptor (CAR) comprising scFv antibody binding to Nectin-2.
    Type: Application
    Filed: January 13, 2020
    Publication date: April 14, 2022
    Inventors: Ofer MANDELBOIM, Pinchas TSUKERMAN, Stipan JONJIC, Tihana LENAC ROVIS, Paola KUCAN BRLIC
  • ANTIBODIES SPECIFIC TO HUMAN T-CELL IMMUNOGLOBULIN AND ITIM DOMAIN (TIGIT)
    Publication number: 20210220472
    Abstract: Natural killer (NK) cell killing of various tumors is inhibited in the presence of ligands of TIGIT, an inhibitory receptor present on all human NK cells and on various T cells. Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions comprising them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.
    Type: Application
    Filed: February 5, 2021
    Publication date: July 22, 2021
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
    Inventors: Ofer MANDELBOIM, Noa S. KAYNAN, Pinchas TSUKERMAN, Stipan JONJIC
  • ANTIBODIES SPECIFIC TO HUMAN NECTIN4
    Publication number: 20210130459
    Abstract: The present invention provides monoclonal antibodies that recognize human Nectin4 with high affinity and specificity and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy and in diagnosis.
    Type: Application
    Filed: May 6, 2019
    Publication date: May 6, 2021
    Inventors: Ofer MANDELBOIM, Adi RECHES, Stipan JONJIC, Pinchas TSUKERMAN
  • ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR)
    Publication number: 20210115150
    Abstract: The present invention provides monoclonal antibodies that recognize polio virus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.
    Type: Application
    Filed: December 10, 2020
    Publication date: April 22, 2021
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
    Inventors: Ofer MANDELBOIM, Noa S. KAYNAN, Pinchas TSUKERMAN, Stipan JONJIC
  • Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
    Patent number: 10946095
    Abstract: Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions including them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: March 16, 2021
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., University of Rijeka Faculty of Medicine
    Inventors: Ofer Mandelboim, Noa S. Kaynan, Pinchas Tsukerman, Stipan Jonjic
  • Antibodies specific to human poliovirus receptor (PVR)
    Patent number: 10906987
    Abstract: The present invention provides monoclonal antibodies that recognize polio virus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: February 2, 2021
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RUEKA FACULTY OF MEDICINE RIJEKA, CROATIA
    Inventors: Ofer Mandelboim, Noa S. Kaynan, Pinchas Tsukerman, Stipan Jonjic
  • ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR)
    Publication number: 20200040092
    Abstract: The present invention provides monoclonal antibodies that recognize polio virus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.
    Type: Application
    Filed: February 28, 2017
    Publication date: February 6, 2020
    Inventors: Ofer MANDELBOIM, Noa S. KAYNAN, Pinchas TSUKERMAN, Stipan JONJIC
  • ANTIBODIES SPECIFIC TO HUMAN T-CELL IMMUNOGLOBULIN AND ITIM DOMAIN (TIGIT)
    Publication number: 20180185480
    Abstract: Provided is a natural killer (NK) cell killing of various tumors is inhibited in the presence of ligands of TIGIT, an inhibitory receptor present on all human NK cells and on various T cells. Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions including them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.
    Type: Application
    Filed: September 1, 2016
    Publication date: July 5, 2018
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., University of Rijeka Faculty of Medicine
    Inventors: Ofer MANDELBOIM, Noa S. KAYNAN, Pinchas TSUKERMAN, Stipan JONJIC